Assessment of Human Leukocyte Antigen-Based Neoantigen Presentation to Determine Pan-Cancer Response to Immunotherapy

Researchers developed a score integrating the binding affinity of neoantigens to human leukocyte antigen class I (HLA-I), as well as HLA-I allele divergence, termed the HLA tumor-Antigen Presentation Score.